Matli, Kamal
Chamoun, Nibal https://orcid.org/0000-0002-0987-296X
Fares, Aya
Zibara, Victor
Al-Osta, Soad
Nasrallah, Rabih
Salameh, Pascale
Mokhbat, Jacques
Ghanem, Georges https://orcid.org/0000-0002-0850-0689
Clinical trials referenced in this document:
Documents that mention this clinical trial
Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection
https://doi.org/10.2215/cjn.14231021
Role of combining anticoagulant and antiplatelet agents in COVID-19 treatment: a rapid review
https://doi.org/10.1136/openhrt-2021-001628
Combined anticoagulant and antiplatelet therapy is associated with an improved outcome in hospitalised patients with COVID-19: a propensity matched cohort study
https://doi.org/10.1136/openhrt-2021-001785
Effect of the P-Selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled Trial
https://doi.org/10.1161/circulationaha.123.065190
Documents that mention this clinical trial
Drug treatments for covid-19: living systematic review and network meta-analysis
https://doi.org/10.1136/bmj.m2980
Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher risk
https://doi.org/10.1136/bmjopen-2020-046799
Role of combining anticoagulant and antiplatelet agents in COVID-19 treatment: a rapid review
https://doi.org/10.1136/openhrt-2021-001628
Atorvastatin versus placebo in patients with covid-19 in intensive care:
randomized controlled trial
https://doi.org/10.1136/bmj-2021-068407
Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia
https://doi.org/10.1007/s00134-025-07861-w
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
https://doi.org/10.1007/s00134-021-06448-5
Combined anticoagulant and antiplatelet therapy is associated with an improved outcome in hospitalised patients with COVID-19: a propensity matched cohort study
https://doi.org/10.1136/openhrt-2021-001785
Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial
https://doi.org/10.1136/thorax-2024-222488
Documents that mention this clinical trial
On-Treatment Change in
<scp>d</scp>
-Dimer Is Associated With Differential Outcomes Among Therapeutic Dose Heparin-Treated Noncritically Ill Patients Hospitalized for COVID-19
https://doi.org/10.1161/atvbaha.124.321108
Role of combining anticoagulant and antiplatelet agents in COVID-19 treatment: a rapid review
https://doi.org/10.1136/openhrt-2021-001628
Combined anticoagulant and antiplatelet therapy is associated with an improved outcome in hospitalised patients with COVID-19: a propensity matched cohort study
https://doi.org/10.1136/openhrt-2021-001785
Documents that mention this clinical trial
On-Treatment Change in
<scp>d</scp>
-Dimer Is Associated With Differential Outcomes Among Therapeutic Dose Heparin-Treated Noncritically Ill Patients Hospitalized for COVID-19
https://doi.org/10.1161/atvbaha.124.321108
Role of combining anticoagulant and antiplatelet agents in COVID-19 treatment: a rapid review
https://doi.org/10.1136/openhrt-2021-001628
Combined anticoagulant and antiplatelet therapy is associated with an improved outcome in hospitalised patients with COVID-19: a propensity matched cohort study
https://doi.org/10.1136/openhrt-2021-001785
Documents that mention this clinical trial
Combined anticoagulant and antiplatelet therapy is associated with an improved outcome in hospitalised patients with COVID-19: a propensity matched cohort study
https://doi.org/10.1136/openhrt-2021-001785